Event Type: The document is a transcript of the Q2 FY27 Earnings Conference Call, hosted by Dolat Capital.

Date and Time: The call was held on 27th October, 2026 from 03:00 p.m. IST to 04:05 p.m. IST.

Purpose: The purpose of the event was to discuss the company's Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30th September, 2026.

Management Participants: The senior management was represented by:

  • Ms. Aditi Panandikar - Managing Director
  • Mr. Sundeep Bambolkar - Joint Managing Director
  • Mr. Pramod Ghorpade – CFO

The moderator was Ms. Rashmi Shetty from Dolat Capital.

Financial Period Discussed: The discussion centered on the results for Q2 FY27 (Quarter Ended 30th September, 2026) and the Half Year (H1 FY27).

Forward-Looking Statements & Compliance: The management began with a standard caution regarding forward-looking statements, noting they are projections subject to risks and uncertainties. The company does not undertake to update them. There was no explicit statement that no Unpublished Price Sensitive Information (UPSI) would be shared.

Key Financial and Operational Highlights from the Call:

Consolidated Performance:

  • Consolidated Net Revenue for Q2 FY27 was ₹5,069 million, up 7.4% YoY (from ₹4,718 million) and marking the first time quarterly revenue crossed ₹500 crore.
  • Consolidated EBITDA was ₹464 million with a margin of 9.2% (vs. 9.1% YoY and 8.8% in Q1 FY27).
  • The margin was partially impacted by an increase in material costs and an additional ₹13 crore freight cost due to ongoing geopolitical conflicts.

Standalone Performance:

  • Standalone Net Revenue for Q2 FY27 was ₹4,381 million, up 2% YoY (from ₹4,293 million).
  • Standalone EBITDA was ₹403 million with a margin of 9.2% (vs. 12.4% YoY and 10.3% in Q1 FY27).

Segment-wise Breakdown (Q2 FY27 vs. Q2 FY26):

  • Domestic Formulations: Revenue declined to ₹2,128 million (from ₹2,261 million). Performance was mixed; therapies like Stomatology (+34.8%) and Gastrointestinal (+30.3%) grew strongly, but this was offset by weakness in anti-infectives and respiratory portfolios.
  • International Formulations: Revenue grew 12.1% to ₹1,720 million (from ₹1,533 million).
  • Regulated Markets: Grew 21.1% to ₹1,109 million (from ₹915 million).
  • US: Grew 16.4% to ₹391 million (from ₹336 million).
  • Europe: Grew 23.5% to ₹675 million (from ₹547 million).
  • South Africa, Australia, NZ: Grew 31.2% to ₹43 million (from ₹33 million).
  • Emerging Markets: Revenue was flat at ₹612 million (from ₹618 million), impacted by the divestment of an ophthalmic portfolio (approx. ₹10-12 crore impact on revenue).
  • API Business: Revenue grew 4.6% to ₹451 million (from ₹431 million).
  • Allied Services (AnaCipher CRO & Indoco Analytical Solutions): Revenue grew 20.8% to ₹82 million (from ₹68 million).

Brand Performance:

  • The flagship brand Cyclopam crossed the ₹200 crore annual sales threshold (MAT basis) and is now at ₹206 crore, maintaining its No. 2 position in its market.
  • Products launched in the last 2 years now contribute nearly ₹100 crore on a MAT basis.

Regulatory Updates:

  • Plant-1, Goa: Successfully cleared an MHRA audit. Regarding the USFDA audit, the company has submitted a comprehensive response. The management expects an outcome by the first week of December 2026 and expressed confidence in a positive resolution.
  • AnaCipher (CRO): Cleared an ANVISA inspection.
  • Warren API Plant: Expecting a USFDA audit by Q2 of the next financial year (likely Q2 FY28).

Strategic & Operational Updates:

  • Debt Reduction: The company reduced consolidated debt by ₹65 crore in H1 FY27.
  • CAPEX & R&D: CAPEX for the year is expected to be minimal (approx. ₹25 crore for physical assets). The apparent ₹60 crore CAPEX in H1 includes capitalization of R&D expenses for ANDA dossiers. R&D spend is controlled at ~4% of revenue YTD.
  • Subsidiary Restructuring: A new company, Warren Life Sciences, has been registered to potentially separate the OTC and API businesses of Warren Remedies for better financial clarity.
  • Capacity Utilization: Management stated the current manufacturing infrastructure can support up to 4x the current international revenue topline.
  • US Business (FPP): The acquired US business turned profitable in H1 FY27, with revenue in excess of ₹100 crore.

Guidance & Outlook:

  • Domestic Business: Aims for high single-digit growth for FY27, dependent on a recovery from seasonal headwinds.
  • International Business: Targets 20%+ growth in regulated markets (Europe/UK). Expects emerging markets to improve in H2.
  • Margins: Focus remains on improving operational efficiencies and profitability, though external cost pressures (freight, materials) persist.

Additional Notes Section

  • The document was an enclosed transcript of the earnings call, submitted as a regulatory filing to the BSE and NSE.
  • The transcript contained the full Q&A session with analysts, covering detailed operational and financial topics.
  • No new financial data was disclosed in this specific announcement document beyond what was presented in the earnings call transcript.
  • The tone of the disclosure was neutral and informative, detailing a scheduled post-results engagement.